Mechanisms of Cocaine Abuse and Toxicity
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Journal of Biological Rhythms Official Publication of the Society for Research on Biological Rhythms
Journal of Biological Rhythms Official Publication of the Society for Research on Biological Rhythms Volume 16, Issue 6 December 2001 EDITORIAL Pebbles of Truth 515 Martin Zatz FEATURE Review Clockless Yeast and the Gears of the Clock: How Do They Mesh? 516 Ruben Baler ARTICLES Resetting of the Circadian Clock by Phytochromes 523 and Cryptochromes in Arabidopsis Marcelo J. Yanovsky, M. Agustina Mazzella, Garry C. Whitelam, and Jorge J. Casal Distinct Pharmacological Mechanisms Leading to c-fos 531 Gene Expression in the Fetal Suprachiasmatic Nucleus Lauren P. Shearman and David R. Weaver Daily Novel Wheel Running Reorganizes and 541 Splits Hamster Circadian Activity Rhythms Michael R. Gorman and Theresa M. Lee Temporal Reorganization of the Suprachiasmatic Nuclei 552 in Hamsters with Split Circadian Rhythms Michael R. Gorman, Steven M. Yellon, and Theresa M. Lee Light-Induced Resetting of the Circadian Pacemaker: 564 Quantitative Analysis of Transient versus Steady-State Phase Shifts Kazuto Watanabe, Tom Deboer, and Johanna H. Meijer Temperature Cycles Induce a Bimodal Activity Pattern in Ruin Lizards: 574 Masking or Clock-Controlled Event? A Seasonal Problem Augusto Foà and Cristiano Bertolucci LETTER Persistence of Masking Responses to Light in Mice Lacking Rods and Cones 585 N. Mrosovsky, Robert J. Lucas, and Russell G. Foster MEETING Eighth Meeting of the Society for Research on Biological Rythms 588 Index 589 Journal of Biological Rhythms Official Publication of the Society for Research on Biological Rhythms EDITOR-IN-CHIEF Martin Zatz FEATURES EDITORS ASSOCIATE EDITORS Larry Morin Michael Hastings SUNY, Stony Brook University of Cambridge Anna Wirz-Justice Ken-Ichi Honma University of Basel Hokkaido Univ School Medicine Michael Young Rockefeller University EDITORIAL BOARD Josephine Arendt Terry Page University of Surrey Vanderbilt University Charles A. -
A Randomised, Non-Inferiority Study of Chloroprocaine 2% and Ropivacaine
www.nature.com/scientificreports OPEN A randomised, non‑inferiority study of chloroprocaine 2% and ropivacaine 0.75% in ultrasound‑guided axillary block Irene Sulyok1, Claudio Camponovo2, Oliver Zotti1, Werner Haslik3, Markus Köstenberger4, Rudolf Likar4, Chiara Leuratti5, Elisabetta Donati6 & Oliver Kimberger1,7* Chloroprocaine is a short‑acting local anaesthetic with a rapid onset of action and an anaesthesia duration up to 60 min. In this pivotal study success rates, onset and remission of motor and sensory block and safety of chloroprocaine 2% was compared to ropivacaine 0.75% for short‑duration distal upper limb surgery with successful block rates as primary outcome. The study was designed as a prospective, randomised, multi‑centre, active‑controlled, double‑blind, parallel‑group, non‑inferiority study, performed in 4 European hospitals with 211 patients scheduled for short duration distal upper limb surgery under axillary plexus block anaesthesia. Patients received either ultrasound guided axillary block with 20 ml chloroprocaine 2%, or with 20 ml ropivacaine 0.75%. Successful block was defned as block without any supplementation in the frst 45 min calculated from the time of readiness for surgery. 90.8% patients achieved a successful block with chloroprocaine 2% and 92.9% patients with Ropivacaine 0.75%, thus non‑inferiority was demonstrated (10% non inferiority margin; 95% CI − 0.097, 0.039; p = 0.02). Time to onset of block was not signifcantly diferent between the groups. Median time to motor and sensory block regression was signifcantly shorter as was time to home discharge (164 [155–170] min for chloroprocaine versus 380 [209–450] for the ropivacaine group, p < 0.001). -
A Review of Effective ADHD Treatment Devin Hilla Grand Valley State University, [email protected]
Grand Valley State University ScholarWorks@GVSU Honors Projects Undergraduate Research and Creative Practice 12-2015 Changing Behavior, Brain Differences, or Both? A Review of Effective ADHD Treatment Devin Hilla Grand Valley State University, [email protected] Follow this and additional works at: http://scholarworks.gvsu.edu/honorsprojects Part of the Medicine and Health Sciences Commons Recommended Citation Hilla, Devin, "Changing Behavior, Brain Differences, or Both? A Review of Effective ADHD Treatment" (2015). Honors Projects. 570. http://scholarworks.gvsu.edu/honorsprojects/570 This Open Access is brought to you for free and open access by the Undergraduate Research and Creative Practice at ScholarWorks@GVSU. It has been accepted for inclusion in Honors Projects by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. Running Head: EFFECTIVE ADHD TREATMENT 1 Changing Behavior, Brain Differences, or Both? A Review of Effective ADHD Treatment Devin Hilla Grand Valley State University Honors Senior Thesis EFFECTIVE ADHD TREATMENT 2 Abstract Much debate exists over the proper course of treatment for individuals with attention- deficit/hyperactivity disorder (ADHD). Stimulant medications, such as methylphenidate (e.g., Ritalin) and amphetamine (e.g., Adderall), have been shown to be effective in managing ADHD symptoms. More recently, non-stimulant medications, such as atomoxetine (e.g., Strattera), clonidine (e.g., Kapvay), and guanfacine (e.g., Intuniv), have provided a pharmacological alternative with potentially lesser side effects than stimulants. Behavioral therapies, like behavioral parent training, behavioral classroom management, and behavioral peer interventions, have shown long-term benefits for children with ADHD; however, the success of the short-term management of ADHD symptoms is not as substantial when compared with stimulant medications. -
510(K) SUBSTANTIAL EQUIVALENCE DETERMINATION CHECKLIST
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k122633 B. Purpose for Submission: New device C. Measurand: d-Amphetamine, Secobarbital, Buprenorphine Glucuroide, Oxazepam, Benzoylecgonine, 3,4-methylenedioxymethamphetamine, Methamphetamine, Methadone, Moprhine, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline, 11-nor-∆9-Tetrahydrocannabinol- 9-carboxylic acid D. Type of Test: Qualitative lateral flow immunoassay E. Applicant: Branan Medical Corporation F. Proprietary and Established Names: ToxCup® Drug Screen Cup G. Regulatory Information: Product Classification Regulation Section Panel Code LDJ II 862.3870 Cannabinoid test system Toxicology (91) DIO II 862.3250 Cocaine and cocaine metabolite Toxicology (91) test system DJG II 862.3650 Opiate test system Toxicology (91) DJC II 862.3610 Methamphetamine test system Toxicology (91) DKZ II 862.3100 Amphetamine test system Toxicology (91) LCM unclassifed Enzyme immunoassay Phencyclidine Toxicology (91) JXM II 862.3170 Benzodiazepine test system Toxicology (91) DIS II 862.3150 Barbiturate test system Toxicology (91) DJR II 862.3620 Methadone test system Toxicology (91) LFG II 862.3910 Tricyclic antidepressant drugs Toxicology (91) test system JXN II 862.3700 Propoxyphene test system Toxicology (91) H. Intended Use: 1. Intended use(s): See indications for use below. 2. Indications(s) for use: The ToxCup Drug Screen Cup is an in vitro screening test for the rapid detection of multiple drugs and drug metabolites in human urine at or above -
ISIS Agent, Sterling Archer, Launches His Pirate King Theme FX Cartoon Series Archer Gets Its First Hip Hop Video Courtesy of Brooklyn Duo, Drop It Steady
ISIS agent, Sterling Archer, launches his Pirate King Theme FX Cartoon Series Archer Gets Its First Hip Hop Video courtesy of Brooklyn duo, Drop it Steady Fans of the FX cartoon series Archer do not need to be told of its genius. The show was created by many of the same writers who brought you the Fox series Arrested Development. Similar to its predecessor, Archer has built up a strong and loyal fanbase. As with most popular cartoons nowadays, hip-hop artists tend to flock to the animated world and Archer now has it's hip-hop spin off. Brooklyn-based music duo, Drop It Steady, created a fun little song and video sampling the show. The duo drew their inspiration from a series sub plot wherein Archer became a "pirate king" after his fiancée was murdered on their wedding day in front of him. For Archer fans, the song and video will definitely touch a nerve as Drop it Steady turns the story of being a pirate king into a forum for discussing recent break ups. Video & Music Download: http://www.mediafire.com/?bapupbzlw1tzt5a Official Website: http://www.dropitsteady.com Drop it Steady on Facebook: http://www.facebook.com/dropitsteady About Drop it Steady: Some say their music played a vital role in the Arab Spring of 2011. Others say the organizers of Occupy Wall Street were listening to their demo when they began to discuss their movement. Though it has yet to be verified, word that the first two tracks off of their upcoming EP, The Most Interesting EP In The World, were recorded at the ceremony for Prince William and Katie Middleton and are spreading through the internets like wild fire. -
Dopamine Reuptake Transporter (DAT) “Inverse Agonism” E Anovel 66 2 67 3 Hypothesis to Explain the Enigmatic Pharmacology of Cocaine 68 4 * 69 5 Q5 David J
NP5526_proof ■ 24 June 2014 ■ 1/22 Neuropharmacology xxx (2014) 1e22 55 Contents lists available at ScienceDirect 56 57 Neuropharmacology 58 59 60 journal homepage: www.elsevier.com/locate/neuropharm 61 62 63 64 65 1 Dopamine reuptake transporter (DAT) “inverse agonism” e Anovel 66 2 67 3 hypothesis to explain the enigmatic pharmacology of cocaine 68 4 * 69 5 Q5 David J. Heal , Jane Gosden, Sharon L. Smith 70 6 71 RenaSci Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK 7 72 8 73 9 article info abstract 74 10 75 11 76 Article history: The long held view is cocaine's pharmacological effects are mediated by monoamine reuptake inhibition. 12 Available online xxx However, drugs with rapid brain penetration like sibutramine, bupropion, mazindol and tesofensine, 77 13 which are equal to or more potent than cocaine as dopamine reuptake inhibitors, produce no discernable 78 14 Keywords: subjective effects such as drug “highs” or euphoria in drug-experienced human volunteers. Moreover 79 15 Cocaine they are dysphoric and aversive when given at high doses. In vivo experiments in animals demonstrate 80 16 Dopamine reuptake inhibitor that cocaine's monoaminergic pharmacology is profoundly different from that of other prescribed 81 Dopamine releasing agent 17 monoamine reuptake inhibitors, with the exception of methylphenidate. These findings led us to 82 Dopamine transporter fi 18 Inverse agonist conclude that the highly unusual, stimulant pro le of cocaine and related compounds, eg methylphe- 83 19 DAT inverse agonist nidate, is not mediated by monoamine reuptake inhibition alone. 84 We describe the experimental findings which suggest cocaine serves as a negative allosteric 20 Novel mechanism 85 21 modulator to alter the function of the dopamine reuptake transporter (DAT) and reverse its direction of fi 86 22 transport. -
Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany). -
Drugs Acting on Nervous System
v DrugsActing on NervousSystem Hyoscyamus Synonym: Hyoscyamus herb, henbane B.S: It consists of dried leaves & flowering tops of the plant Hyoscyamus niger, family Solanaceae. It should contain not less than 0.05% of total alkaloids calculated as hyoscyamine. C.C: It contains alkaloids hyoscyamine, hyoscine ( scopolamine) & atropine. Uses: It is used to counteract gripping due to purgatives & also to relieve spasms of the urinary tract. It is also sedative & used to check salivary secretions. It is an antispasmodic & anti- asthamatic. Substitutes: Egyptian henbane. Datura Synonym: Datura herb B.S: It consists of dried leaves & flowering tops of the plant Datura metel variety fastuosa Safford, family Solanaceae. It should contain not less than 0.5% of total alkaloids calculated as hyoscyamine. C.C: It contains alkaloids ,hyoscine ( scopolamine) . Only small quantities of hyoscyamine& atropine are present. Uses: The drug is parasympathetic depressant. It is used in the treatment of asthma & cough. It is also an antispa smodic & a CNS depressant. Chemical test (Vitali-Morin Reaction) 1.Tropane alkaloid is treated with fuming nitric acid, followed by evaporation to dryness & addition of methanolic KoH solution to an acetone solution of nitrated residue. Violet coloration takes place due to tropane derivative. 2.On addition of silver nitrate soln to soln of hyoscine hydrobromide, yellowish white ppt is formed, which is insoluble in nitric acid, but soluble in dilute ammonia. Belladonna herb Synonym: Belladonna leaf, Deadly night shade B.S: It consists of dried leaves or the leaves & other aerial parts of the plant Atropa belladonna or Atropa acuminata or mixture of both the species collected when the plant are in flowering stage, family Solanaceae. -
The Alkaloids: Chemistry and Biology
CONTRIBUTORS Numbers in parentheses indicate the pages on which the authors’ contributions begin. B. EMMANUEL AKINSHOLA (135), Department of Pharmacology, College of Medicine, Howard University, Washington, DC 20059, eakinshola@ howard.edu NORMA E. ALEXANDER (293), NDA International, 46 Oxford Place, Staten Island, NY 10301, [email protected] SYED F. ALI (79, 135), Division of Neurotoxicology, National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, [email protected] KENNETH R. ALPER (1, 249), Departments of Psychiatry and Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, [email protected] MICHAEL H. BAUMANN (79), Clinical Psychopharmacology Section, Intra- mural Research Program, NIDA, National Institutes of Health, Baltimore, MD 21224, [email protected] DANA BEAL (249), Cures-not-Wars, 9 Bleecker Street, New York, NY 10012, [email protected] ZBIGNIEW K. BINIENDA (193), Division of Neurotoxicology, National Cen- ter for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, [email protected] WAYNE D. BOWEN (173), Laboratory of Medicinal Chemistry, NIDDK, NIH, Building 8 B1-23, 8 Center Drive, MSC 0820, Bethesda, MD 20892, [email protected] FRANK R. ERVIN (155), Department of Psychiatry and Human Genetics, McGill University, Montreal, Quebec H3A 2T5, Canada, md18@musica. mcgill.ca JAMES W. FERNANDEZ (235), Department of Anthropology, University of Chicago, 1126 E. 59th Street, Chicago, IL 60637, jwfi@midway. uchicago.edu xi xii CONTRIBUTORS RENATE L. FERNANDEZ (235), Department of Anthropology, University of Chicago, 1126 E. 59th Street, Chicago, IL 60637, rlf2@midway. uchicago.edu GEERTE FRENKEN (283), INTASH, P.O. -
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
County Contact Information Updated October 8, 2020
County Contact Information Updated October 8, 2020 County District Area Engineer Anderson Tyler Frierson Tymli Andrews Odessa Beeman Thomas Angelina Lufkin Frierson Tymli Aransas Corpus Christi Arocho Valeria Archer Wichita Falls Rodriguez Yamayra Armstrong Amarillo Rodriguez Yamayra Atascosa San Antonio Pratt Samantha Austin Yoakum Pratt Samantha Bailey Lubbock Beeman Thomas Bandera San Antonio Pratt Samantha Bastrop Austin Ham Justin Baylor Wichita Falls Rodriguez Yamayra Bee Corpus Christi Arocho Valeria Bell Waco Rodriguez Yamayra Bexar San Antonio Pratt Samantha Blanco Austin Ham Justin Borden Abilene Beeman Thomas Bosque Waco Rodriguez Yamayra Bowie Atlanta Frierson Tymli Brazoria Houston Pratt Philip Brazos Bryan Pratt Philip Brewster El Paso Beeman Thomas Briscoe Childress Rodriguez Yamayra Brooks Pharr Patel Ujval Brown Brownwood Ham Justin Burleson Bryan Pratt Philip Calhoun Yoakum Pratt Samantha Callahan Abilene Beeman Thomas Cameron Pharr Patel Ujval Camp Atlanta Frierson Tymli Carson Amarillo Rodriguez Yamayra Cass Atlanta Frierson Tymli Castro Lubbock Beeman Thomas Chambers Beaumont Rumancik Clarence Cherokee Tyler Frierson Tymli Childress Childress Rodriguez Yamayra Cochran Lubbock Beeman Thomas Coke San Angelo Arocho Valeria Coleman Brownwood Ham Justin County District Area Engineer Collin Dallas Patel Ujval Collingsworth Childress Rodriguez Yamayra Colorado Yoakum Pratt Samantha Comal San Antonio Pratt Samantha Comanche Brownwood Ham Justin Concho San Angelo Arocho Valeria Cooke Wichita Falls Rodriguez Yamayra Coryell -
Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.